\-\ Texto\\:\\ \ \(0\)\
\-\ not\\ available\\.\ \(14\)\
\-\ surgical\\ resection\ \(126\)\
\-\ film\\ \\#1\\:\\ non\\-enhanced\\ ct\\ image\\ shows\\ a\\ slightly\\ decreased\\ attenuating\\ focal\\ mass\\ in\\ the\\ pancreatic\\ body\\ with\\ diffuse\\ atrophic\\ changes\\.\\ several\\ enlarged\\ peripancreatic\\ lymph\\ nodes\\ are\\ present\\ with\\ the\\ largest\\ measuring\\ 13\\ mm\\ on\\ short\\ axis\\ diameter\\.\ \(0\)\
\-\ film\\ \\#2\\:\\ dynamic\\ contrast\\-enhanced\\ ct\\ image\\ shows\\ a\\ 2\\.5\\ x\\ 4\\.3\\ cm\\ unenhancing\\,\\ hypodense\\ mass\\ in\\ the\\ pancreatic\\ body\\.\\ no\\ metastases\\ were\\ seen\\ in\\ the\\ liver\\.\\ \ \(0\)\
\-\ film\\ \\#3\\:\\ dynamic\\ contrast\\-enhanced\\ ct\\ image\\ \\(on\\ liver\\ window\\)\\ shows\\ a\\ 7\\ mm\\ obstructed\\ pancreatic\\ duct\\ \\(arrow\\)\\ surrounded\\ by\\ contrast\\-enhanced\\ pancreatic\\ parenchyma\\ seen\\ distal\\ to\\ the\\ pancreatic\\ mass\\.\ \(0\)\
\-\ pancreatic\\ ductal\\ adenocarcinoma\ \(0\)\
\-\ 1\\.\\)most\\ exocrine\\ pancreatic\\ tumors\\;\\ 2\\.\\)lymphoma\\;\\ 3\\.\\)pancreatic\\ endocrine\\ tumors\\ \\(mostly\\ non\\-functional\\)\\.\ \(0\)\
\-\ 56\\ year\\ old\\ male\\ with\\ severe\\ upper\\ abdominal\\ pain\\,\\ left\\ greater\\ than\\ right\\,\\ for\\ 1\\ week\\.\ \(1\)\
\-\ a\\ majority\\ of\\ non\\-endocrine\\ pancreatic\\ carcinomas\\,\\ up\\ to\\ 75\\-85\\%\\,\\ are\\ ductal\\ cell\\ adenocarcinomas\\[1\\,2\\]\\.\\ the\\ tumor\\ is\\ highly\\ lethal\\ and\\ is\\ usually\\ unresectable\\ at\\ presentation\\.\\ the\\ average\\ survival\\ time\\ of\\ a\\ patient\\ with\\ this\\ disease\\ is\\ only\\ 8\\ months\\ or\\ less\\.\\ these\\ tumors\\ usually\\ occur\\ in\\ the\\ seventh\\ decade\\ of\\ life\\.\\ \\ \ \(0\)\
\-\ currently\\,\\ computed\\ tomography\\ \\(ct\\)\\ is\\ the\\ most\\ commonly\\ used\\ imaging\\ method\\ in\\ the\\ assessment\\ of\\ pancreatic\\ tumors\\.\\ the\\ sensitivity\\ of\\ ct\\ detection\\ of\\ pancreatic\\ tumors\\ is\\ reported\\ to\\ be\\ more\\ than\\ 90\\%\\ when\\ direct\\ or\\ indirect\\ signs\\ are\\ used\\ for\\ diagnosis\\[1\\]\\.\\ however\\,\\ the\\ potential\\ to\\ differentiate\\ exocrine\\ \\(non\\-endocrine\\)\\ tumors\\ of\\ the\\ pancreas\\ is\\ limited\\.\\ \ \(0\)\
\-\ on\\ non\\-enhanced\\ ct\\ imaging\\,\\ there\\ is\\ often\\ a\\ slightly\\ decreased\\ attenuating\\ pancreatic\\ mass\\ seen\\.\\ following\\ rapid\\ bolus\\ of\\ contrast\\ injection\\,\\ the\\ tumor\\ usually\\ appears\\ as\\ a\\ hypodense\\ mass\\ with\\ ill\\-defined\\ borders\\.\\ calcification\\ is\\ almost\\ never\\ present\\ within\\ the\\ mass\\.\\ indirect\\ signs\\ of\\ a\\ pancreatic\\ mass\\ include\\ abrupt\\ obstruction\\ of\\ the\\ common\\ bile\\ and\\/or\\ pancreatic\\ duct\\ and\\ atrophy\\ of\\ pancreatic\\ tissue\\ beyond\\ the\\ tumor\\.\\ the\\ typical\\ distribution\\ of\\ ductal\\ cell\\ adenocarcinoma\\ is\\ as\\ follows\\:\\ 60\\â\\€\\“70\\%\\ at\\ the\\ pancreatic\\ head\\,\\ 10\\%\\ the\\ body\\,\\ 5\\%\\ the\\ tail\\,\\ 5\\%\\ both\\ head\\ and\\ body\\,\\ and\\ about\\ 10\\%\\ body\\ and\\ tail\\ \\[1\\]\\.\\ \ \(0\)\
\-\ those\\ who\\ present\\ with\\ a\\ pancreatic\\ head\\ mass\\ often\\ have\\ symptoms\\ earlier\\ than\\ in\\ those\\ with\\ pancreatic\\ tail\\ masses\\,\\ mainly\\ due\\ to\\ symptomatic\\ obstruction\\ of\\ the\\ biliary\\ or\\ pancreatic\\ duct\\.\\ radiographic\\ assessment\\ of\\ resectability\\ is\\ critical\\ because\\ surgical\\ resection\\ offers\\ the\\ only\\ hope\\ of\\ cure\\[2\\]\\.\\ \\ however\\,\\ the\\ surgery\\ itself\\ carries\\ a\\ high\\ morbidity\\.\\ resectable\\ patients\\ may\\ live\\ 1\\-2\\ years\\.\\ signs\\ of\\ potential\\ resectability\\ include\\ an\\ isolated\\ pancreatic\\ mass\\ with\\ or\\ without\\ dilation\\ of\\ the\\ bile\\ or\\ pancreatic\\ ducts\\ or\\ combined\\ dilation\\ of\\ both\\ the\\ bile\\ and\\ pancreatic\\ ducts\\ without\\ an\\ identifiable\\ pancreatic\\ head\\ mass\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ pancreatic\\:\\ 0\\.7205571010754589\ \(0\)\
\-\ the\\:\\ 0\\.1792855117083736\ \(0\)\
\-\ tumors\\:\\ 0\\.15249429757396757\ \(0\)\
\-\ mass\\:\\ 0\\.1320027827345507\ \(0\)\
\-\ of\\:\\ 0\\.12173167070914973\ \(0\)\
\-\ body\\:\\ 0\\.1137185755180504\ \(0\)\
\-\ endocrine\\:\\ 0\\.11276863447987523\ \(0\)\
\-\ tail\\:\\ 0\\.10225034229834191\ \(0\)\
\-\ resectability\\:\\ 0\\.10213347181901145\ \(0\)\
\-\ bile\\:\\ 0\\.10066894806208526\ \(0\)\
\-\ exocrine\\:\\ 0\\.09942977997154044\ \(0\)\
\-\ is\\:\\ 0\\.09463975211887286\ \(0\)\
\-\ ductal\\:\\ 0\\.09123408558206056\ \(0\)\
\-\ duct\\:\\ 0\\.08924425688646982\ \(0\)\
\-\ indirect\\:\\ 0\\.08785244112902903\ \(0\)\
\-\ attenuating\\:\\ 0\\.08533660388229408\ \(0\)\
\-\ or\\:\\ 0\\.08415507558624469\ \(0\)\
\-\ head\\:\\ 0\\.08244488017996081\ \(0\)\
\-\ ct\\:\\ 0\\.07893959830280942\ \(0\)\
\-\ dynamic\\:\\ 0\\.07813090714860847\ \(0\)\
\-\ film\\:\\ 0\\.07747286496831182\ \(0\)\
\-\ signs\\:\\ 0\\.0724569378966934\ \(0\)\
\-\ ducts\\:\\ 0\\.07129085008073677\ \(0\)\
\-\ assessment\\:\\ 0\\.06762830046137325\ \(0\)\
\-\ contrast\\:\\ 0\\.06716433444108605\ \(0\)\
\-\ hypodense\\:\\ 0\\.06711263204139017\ \(0\)\
\-\ image\\:\\ 0\\.06630355834920917\ \(0\)\
\-\ usually\\:\\ 0\\.06526684572942279\ \(0\)\
\-\ potential\\:\\ 0\\.06175921894364652\ \(0\)\
\-\ shows\\:\\ 0\\.0608478757359594\ \(0\)\
\-\ dilation\\:\\ 0\\.060822723721373706\ \(0\)\
\-\ those\\:\\ 0\\.059142383231823865\ \(0\)\
\-\ than\\:\\ 0\\.05877004250896498\ \(0\)\
\-\ adenocarcinoma\\:\\ 0\\.0564911055066262\ \(0\)\
\-\ unenhancing\\:\\ 0\\.05526595289368507\ \(0\)\
\-\ tumor\\:\\ 0\\.054227701184283605\ \(0\)\
\-\ with\\:\\ 0\\.05413529126817395\ \(0\)\
\-\ slightly\\:\\ 0\\.05391414045221006\ \(0\)\
\-\ present\\:\\ 0\\.05319867721372031\ \(0\)\
\-\ used\\:\\ 0\\.051742868008859313\ \(0\)\
\-\ in\\:\\ 0\\.05158162819332701\ \(0\)\
\-\ and\\:\\ 0\\.04998708293224322\ \(0\)\
\-\ mm\\:\\ 0\\.049463003694153705\ \(0\)\
\-\ seen\\:\\ 0\\.04880904544973523\ \(0\)\
\-\ adenocarcinomas\\:\\ 0\\.04861035144136943\ \(0\)\
\-\ obstruction\\:\\ 0\\.04841200894256812\ \(0\)\
\-\ liver\\:\\ 0\\.04767957315065531\ \(0\)\
\-\ unresectable\\:\\ 0\\.04767647740854065\ \(0\)\
\-\ offers\\:\\ 0\\.04767647740854065\ \(0\)\
\-\ hope\\:\\ 0\\.046153966973233124\ \(0\)\
\-\ lethal\\:\\ 0\\.04551567300159087\ \(0\)\
\-\ often\\:\\ 0\\.04509833873111405\ \(0\)\
\-\ peripancreatic\\:\\ 0\\.044938265869275636\ \(0\)\
\-\ bolus\\:\\ 0\\.044938265869275636\ \(0\)\
\-\ resectable\\:\\ 0\\.044938265869275636\ \(0\)\
\-\ resection\\:\\ 0\\.04430440550135362\ \(0\)\
\-\ cure\\:\\ 0\\.04392622056451451\ \(0\)\
\-\ arrow\\:\\ 0\\.0434772604243613\ \(0\)\
\-\ to\\:\\ 0\\.043197307217766996\ \(0\)\
\-\ only\\:\\ 0\\.0431799026019949\ \(0\)\
\-\ live\\:\\ 0\\.043059288533454566\ \(0\)\
\-\ decreased\\:\\ 0\\.04281201463638034\ \(0\)\
\-\ seventh\\:\\ 0\\.04266830194114704\ \(0\)\
\-\ carries\\:\\ 0\\.04266830194114704\ \(0\)\
\-\ include\\:\\ 0\\.04112353032407642\ \(0\)\
\-\ however\\:\\ 0\\.040908729904957496\ \(0\)\
\-\ atrophic\\:\\ 0\\.040739048885096295\ \(0\)\
\-\ identifiable\\:\\ 0\\.040739048885096295\ \(0\)\
\-\ 10\\:\\ 0\\.040415663664283306\ \(0\)\
\-\ cell\\:\\ 0\\.03953767055096631\ \(0\)\
\-\ are\\:\\ 0\\.039339701469502525\ \(0\)\
\-\ obstructed\\:\\ 0\\.039065453574304236\ \(0\)\
\-\ mainly\\:\\ 0\\.038860071549275225\ \(0\)\
\-\ carcinomas\\:\\ 0\\.038661424588329205\ \(0\)\
\-\ both\\:\\ 0\\.03854260721780156\ \(0\)\
\-\ method\\:\\ 0\\.03810180950850468\ \(0\)\
\-\ critical\\:\\ 0\\.03810180950850468\ \(0\)\
\-\ abrupt\\:\\ 0\\.03792619751644644\ \(0\)\
\-\ morbidity\\:\\ 0\\.03711723903323218\ \(0\)\
\-\ without\\:\\ 0\\.03645621518241971\ \(0\)\
\-\ decade\\:\\ 0\\.03640368708113892\ \(0\)\
\-\ differentiate\\:\\ 0\\.03640368708113892\ \(0\)\
\-\ never\\:\\ 0\\.03640368708113892\ \(0\)\
\-\ imaging\\:\\ 0\\.03632292033932257\ \(0\)\
\-\ mostly\\:\\ 0\\.03614024603176643\ \(0\)\
\-\ average\\:\\ 0\\.03601270048883139\ \(0\)\
\-\ detection\\:\\ 0\\.03601270048883139\ \(0\)\
\-\ beyond\\:\\ 0\\.03601270048883139\ \(0\)\
\-\ most\\:\\ 0\\.03597018142909292\ \(0\)\
\-\ window\\:\\ 0\\.035527786596155825\ \(0\)\
\-\ surrounded\\:\\ 0\\.035527786596155825\ \(0\)\
\-\ largest\\:\\ 0\\.03518798597718143\ \(0\)\
\-\ sensitivity\\:\\ 0\\.03507882645600261\ \(0\)\
\-\ itself\\:\\ 0\\.03507882645600261\ \(0\)\
\-\ borders\\:\\ 0\\.034762675273119596\ \(0\)\
\-\ combined\\:\\ 0\\.034269867972788345\ \(0\)\
\-\ follows\\:\\ 0\\.033814150230686624\ \(0\)\
\-\ survival\\:\\ 0\\.033726980532267095\ \(0\)\
\-\ surgical\\:\\ 0\\.033592744592700924\ \(0\)\
\-\ tomography\\:\\ 0\\.03347275346112502\ \(0\)\
\-\ axis\\:\\ 0\\.033390327842445736\ \(0\)\
\-\ computed\\:\\ 0\\.03330900864136036\ \(0\)\
\-\ isolated\\:\\ 0\\.03284276406860183\ \(0\)\
\-\ atrophy\\:\\ 0\\.03269499602293938\ \(0\)\
\-\ pancreas\\:\\ 0\\.03247988977508625\ \(0\)\
\-\ 56\\:\\ 0\\.03227216006953233\ \(0\)\
\-\ rapid\\:\\ 0\\.032137528095190736\ \(0\)\
\-\ biliary\\:\\ 0\\.032137528095190736\ \(0\)\
\-\ earlier\\:\\ 0\\.03156617612531732\ \(0\)\
\-\ majority\\:\\ 0\\.0313871032993925\ \(0\)\
\-\ on\\:\\ 0\\.031311433819480705\ \(0\)\
\-\ almost\\:\\ 0\\.031044095309204732\ \(0\)\
\-\ highly\\:\\ 0\\.03093394337430943\ \(0\)\
\-\ direct\\:\\ 0\\.03046163758091653\ \(0\)\
\-\ injection\\:\\ 0\\.030070650988609005\ \(0\)\
\-\ short\\:\\ 0\\.02970337554014599\ \(0\)\
\-\ nodes\\:\\ 0\\.029357099036515743\ \(0\)\
\-\ distribution\\:\\ 0\\.029315173682210035\ \(0\)\
\-\ life\\:\\ 0\\.02835152961641048\ \(0\)\
\-\ parenchyma\\:\\ 0\\.028072943085352988\ \(0\)\
\-\ metastases\\:\\ 0\\.02793831111101139\ \(0\)\
\-\ diameter\\:\\ 0\\.027774122484095245\ \(0\)\
\-\ as\\:\\ 0\\.027766444403693278\ \(0\)\
\-\ 90\\:\\ 0\\.027614266520472695\ \(0\)\
\-\ limited\\:\\ 0\\.027582795335316296\ \(0\)\
\-\ lymph\\:\\ 0\\.02687273211900543\ \(0\)\
\-\ measuring\\:\\ 0\\.02673472639013009\ \(0\)\
\-\ typical\\:\\ 0\\.026707498526236113\ \(0\)\
\-\ symptomatic\\:\\ 0\\.02657316509517504\ \(0\)\
\-\ currently\\:\\ 0\\.026546652188444667\ \(0\)\
\-\ an\\:\\ 0\\.02642981610963792\ \(0\)\
\-\ at\\:\\ 0\\.026106076800259222\ \(0\)\
\-\ 13\\:\\ 0\\.026063773635791165\ \(0\)\
\-\ about\\:\\ 0\\.025871434004429657\ \(0\)\
\-\ radiographic\\:\\ 0\\.025639291062346255\ \(0\)\
\-\ commonly\\:\\ 0\\.0255713480378523\ \(0\)\
\-\ greater\\:\\ 0\\.02545977601666733\ \(0\)\
\-\ occur\\:\\ 0\\.025415716262327928\ \(0\)\
\-\ appears\\:\\ 0\\.025306948717437206\ \(0\)\
\-\ reported\\:\\ 0\\.024890414289941824\ \(0\)\
\-\ calcification\\:\\ 0\\.02467296815966083\ \(0\)\
\-\ because\\:\\ 0\\.024152312632231134\ \(0\)\
\-\ presentation\\:\\ 0\\.02378923115383434\ \(0\)\
\-\ enlarged\\:\\ 0\\.02355872874926616\ \(0\)\
\-\ masses\\:\\ 0\\.023526504260954335\ \(0\)\
\-\ less\\:\\ 0\\.023510456067414354\ \(0\)\
\-\ available\\:\\ 0\\.02344668506258716\ \(0\)\
\-\ week\\:\\ 0\\.023243946803482143\ \(0\)\
\-\ several\\:\\ 0\\.022673515134826083\ \(0\)\
\-\ severe\\:\\ 0\\.021876783072550136\ \(0\)\
\-\ diffuse\\:\\ 0\\.021672217020250305\ \(0\)\
\-\ years\\:\\ 0\\.021183663482215228\ \(0\)\
\-\ for\\:\\ 0\\.020948600264917003\ \(0\)\
\-\ changes\\:\\ 0\\.02088548501244557\ \(0\)\
\-\ when\\:\\ 0\\.020875102508586988\ \(0\)\
\-\ following\\:\\ 0\\.02073158538547302\ \(0\)\
\-\ focal\\:\\ 0\\.020671103789767588\ \(0\)\
\-\ lymphoma\\:\\ 0\\.020581498695833804\ \(0\)\
\-\ time\\:\\ 0\\.020483467600208558\ \(0\)\
\-\ months\\:\\ 0\\.02011562016576404\ \(0\)\
\-\ distal\\:\\ 0\\.020079124937814437\ \(0\)\
\-\ due\\:\\ 0\\.01986465335441307\ \(0\)\
\-\ cm\\:\\ 0\\.019847118784954404\ \(0\)\
\-\ high\\:\\ 0\\.019640569591148307\ \(0\)\
\-\ common\\:\\ 0\\.019598410830068726\ \(0\)\
\-\ who\\:\\ 0\\.019548204552237\ \(0\)\
\-\ these\\:\\ 0\\.019514963374085207\ \(0\)\
\-\ patients\\:\\ 0\\.019440830966172183\ \(0\)\
\-\ more\\:\\ 0\\.018976102646586043\ \(0\)\
\-\ symptoms\\:\\ 0\\.018908244182697098\ \(0\)\
\-\ abdominal\\:\\ 0\\.01890075105926974\ \(0\)\
\-\ surgery\\:\\ 0\\.018579905523076073\ \(0\)\
\-\ upper\\:\\ 0\\.01846732268698756\ \(0\)\
\-\ tissue\\:\\ 0\\.018128409408370905\ \(0\)\
\-\ diagnosis\\:\\ 0\\.017914683070822217\ \(0\)\
\-\ were\\:\\ 0\\.017813710908148813\ \(0\)\
\-\ may\\:\\ 0\\.017390734316818104\ \(0\)\
\-\ have\\:\\ 0\\.017263675160581457\ \(0\)\
\-\ up\\:\\ 0\\.017094598432931183\ \(0\)\
\-\ within\\:\\ 0\\.015916403181584694\ \(0\)\
\-\ male\\:\\ 0\\.015386603215409434\ \(0\)\
\-\ by\\:\\ 0\\.014675380888231901\ \(0\)\
\-\ disease\\:\\ 0\\.01450626995777334\ \(0\)\
\-\ be\\:\\ 0\\.014018846632054495\ \(0\)\
\-\ there\\:\\ 0\\.01375056762529849\ \(0\)\
\-\ not\\:\\ 0\\.013642722660350078\ \(0\)\
\-\ pain\\:\\ 0\\.012366166155598199\ \(0\)\
\-\ this\\:\\ 0\\.011874791446497054\ \(0\)\
\-\ left\\:\\ 0\\.01178852752518329\ \(0\)\
\-\ right\\:\\ 0\\.011457445757412027\ \(0\)\
\-\ patient\\:\\ 0\\.011240020702356655\ \(0\)\
\-\ no\\:\\ 0\\.011237906519987026\ \(0\)\
\-\ year\\:\\ 0\\.01065013136200523\ \(0\)\
\-\ old\\:\\ 0\\.01022781274198562\ \(0\)\
